MGTX
MeiraGTx Holdings plc
Biotechnology · Healthcare · United States
12.88
close · 2026-09-14
value
70
cheaper than peers70
quality
96
stronger fundamentals96
ranked against
Biotechnology (commercial)
value
quality
159 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 3.40× | 85 |
| EV to EBITDA | 6.79× | 71 |
| price to book | 5.63× | 38 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 76.0% | 99 |
| revenue growth | 8608.6% | 97 |
| return on equity | 72.2% | 97 |
| debt to equity | 52.1% | 30 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | $56.4M |
| employees | 393 |
| first trade | 2018-06-08 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-09-02 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.42 | -2.12 | -1.49 | -2.87 |
| free cash flow | -$50.6M | -$109.5M | -$125.5M | -$118.1M |
| net income | -$114.2M | -$147.8M | -$84.0M | -$129.6M |
| revenue | $81.4M | $33.3M | $14.0M | $15.9M |
| unusual items | $2.1M | $25.5M | $63.5M | -$9.1M |